CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
The dynamics of CAR T-cell therapy in ALL in the market are anticipated to change in the coming years owing to improvements in research and development activities for efficient treatment options to be available in the market. The launch of emerging therapies such as Lasme-cel (UCART22) (Cellectis), WU-CART-007 (Wugen), CTD402 (Imviva), Obe-cel and AUTO1/22 (Autolus Therapeutics), and others is expected during the forecast period of 2025–2034.
LAS VEGAS, Aug. 12, 2026 /PRNewswire/ -- Recently published CAR T-Cell Therapy for ALL Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-cell therapy for ALL emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
CAR T-Cell Therapy for ALL Market Summary
Discover what is the future of the CAR T-cell therapy for ALL treatment market @ https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Key Factors Driving the Growth of the CAR T-Cell Therapy for ALL Market
As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, CAR-T cell therapies need more data supporting their use in earlier lines of therapy. Patients are likely to have better outcomes if they receive CAR-T cell therapy before multiple lines of chemotherapy, like those in the clinical trials that led to FDA approval. Moreover, even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, they have successfully reached the majority of the markets by considering the patient pool demand.
CAR T-Cell Therapy for ALL Market Analysis
CAR T-Cell Therapy for ALL Competitive Landscape
Some of the CAR T-cell therapies for ALL under development include Lasme-cel (UCART22) (Cellectis), WU-CART-007 (Wugen), CTD402 (Imviva), Obe-cel and AUTO1/22 (Autolus Therapeutics), FT839 (Fate Therapeutics), PMB-101 (PeproMene Bio), and others.
Cellectis' Lasme-cel is expected to address a significant share of the eligible market by offering several potential advantages over CD19-directed therapies, including a distinct therapeutic target, a single-dose treatment approach, off-the-shelf availability, and the ability to achieve deep minimal residual disease (MRD) responses in patients receiving third-line or later therapy.
Wugen's WU-CART-007 is an investigational allogeneic, off-the-shelf CAR-T cell therapy targeting CD7. It has been engineered with a fratricide-resistant design to overcome key manufacturing and biological challenges associated with developing CAR-T therapies for CD7-positive hematologic malignancies. In August 2025, Wugen secured USD 115 million through an equity financing round led by Fidelity Management & Research Company, with additional investments from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other prominent life sciences investors. The funding is intended to accelerate the ongoing pivotal T-RRex trial evaluating WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
The anticipated launch of these emerging therapies are poised to transform the CAR T-cell therapy for ALL market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CAR T-cell therapy for ALL market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which pipeline drugs could transform CAR T-cell therapy for ALL treatment @ CAR T-Cell Therapy for ALL Drugs
Recent Developments in the CAR T-Cell Therapy for ALL Market
CAR T-Cell Therapy for ALL Epidemiology Segmentation
The CAR T-cell therapy for ALL epidemiology section provides insights into the historical and current CAR T-cell therapy for ALL patient pool and forecasted trends for the leading markets. Among the type-specific cases of ALL in the EU4 and the UK, B-cell lymphoblastic leukemia cases were almost 4 times higher than cases of T-cell lymphoblastic leukemia in 2025.
The CAR T-cell therapy for ALL treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
CAR T-Cell Therapy for ALL Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
CAR T-Cell Therapy for ALL Market CAGR
6.8 %
CAR T-Cell Therapy for ALL Market Size in 2025
USD 300 Million
Key CAR T-Cell Therapy for ALL Companies
Cellectis, Wugen, Imviva, Autolus Therapeutics, Fate Therapeutics, PeproMene Bio, Gilead Sciences (Kite Pharmaceuticals), Novartis, and others
Key CAR T-Cell Therapy for ALL Therapies
Lasme-cel (UCART22), WU-CART-007, CTD402, Obe-cel, AUTO1/22, FT839, PMB-101, TECARTUS, KYMRIAH, and others
Scope of the CAR T-Cell Therapy for ALL Market Report
Download the report to understand the top emerging CAR T-cell therapies for ALL @ CAR T-Cell Therapy for ALL Clinical Trials
Table of Contents
1
CAR T-Cell Therapy for ALL Market Key Insights
2
CAR T-Cell Therapy for ALL Market Report Introduction
3
Executive Summary of CAR-T in ALL
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
CAR-T in ALL Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2
Market Share (%) Distribution of CAR-T Cell Therapy in ALL By Therapies in the 7MM, in 2025
6.3
Market Share (%) Distribution of CAR-T Cell Therapy in ALL By Therapies in the 7MM, in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Diagnosis of ALL
7.3
Bone Marrow Tests
7.4
Lab Tests used to Diagnose and Classify ALL
7.5
Chromosome Tests
7.6
Imaging Tests
7.7
Stages of ALL
8
Current Treatment Practices: ALL
8.1
CAR-T Cell Therapy
8.2
Other Treatment Options
8.3
Treatment Guidelines
9
Epidemiology and Patient Population of ALL
9.1
Key Findings
9.1.1
Assumptions and Rationale
9.1.2
Total Incident Cases of ALL in the 7MM
9.2
The United States
9.2.1
Total Incident Cases of ALL in the US
9.2.2
Gender-specific Incident Cases of ALL in the US
9.2.3
Age-specific Incident Cases of ALL in the US
9.2.4
Subtype-specific Incident Cases of ALL in the US
9.2.5
Genetic mutation-specific Incident Cases of ALL in the US
9.2.6
Total Treated Cases of ALL in the US
9.3
EU4 and the UK
9.4
Japan
10
Patient Journey
10.1
CAR-T Cell Patient Journey
11
Marketed CAR T-Cell Therapies for ALL
11.1
Competitive Landscape of Marketed CAR-T therapies
11.2
KYMRIAH (tisagenlecleucel): Novartis
11.3.1
Drug Description
11.3.2
Regulatory Milestones
11.3.3
Other Developmental Activities
11.3.4
Summary of Pivotal Trials
11.3.5
Clinical Development
11.3.5.1
Clinical Trial Information
11.3.6
Analyst Views
11.2.6
Product Profile
11.3
TECARTUS (brexucabtagene autoleucel): Gilead Sciences
11.4
AUCATZYL (obecabtagene autoleucel): Autolus Therapeutics
12
Emerging CAR T-Cell Therapies for ALL
12.1
Competitive Landscape of Emerging CAR-T Therapies
12.2
Lasmecabtagene timgedleucel (Lasme-cel/UCART22): Cellectis
12.2.1
Drug Description
12.2.2
Other Developmental Activity
12.2.3
Clinical Development
12.2.3.1
Clinical Trials Information
12.2.4
Analyst Views
12.3
WU-CART-007 (soficabtagene geleucel/sofi-cel): Wugen
13
CAR T-Cell Therapy for ALL Market : 7MM Analysis
13.1
Key Findings
13.2
CAR T-Cell Therapy for ALL Market Outlook
13.3
Conjoint Analysis
13.4
Key CAR T-Cell Therapy for ALL Market Forecast Assumptions
13.5
Total Market Size of CAR-T Cell Therapies in ALL in the 7MM
13.6
United States CAR T-Cell Therapy for ALL Market Size
13.6.1
Total Market Size of CAR-T Cell Therapies in ALL in the United States
13.6.2
Total Market Size by Therapies in the United States
13.7
EU4 and the UK CAR T-Cell Therapy for ALL Market Size
13.8
Japan CAR T-Cell Therapy for ALL Market Size
14
Unmet Needs of CAR-T Cell Therapies in ALL
15
SWOT Analysis of CAR-T Cell Therapies in ALL
16
KOL Views of CAR-T Cell Therapies in ALL
17
Market Access and Reimbursement of CAR-T Cell Therapies in ALL
17.1
United States
17.2
EU4 and the UK
17.3
Japan
17.4
Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement of CAR-T Cell Therapy in ALL Therapies
18
Bibliography
19
CAR T-Cell Therapy for ALL Market Report Methodology
Related Reports
CAR T-Cell Therapy Market
CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, and others.
CAR-T Market
CAR-T Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR-T companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, and others.
Acute Lymphoblastic Leukemia Market
Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALL companies, including AbbVie, Roche (Genentech), Janssen Research & Development, Pharmacyclics (an AbbVie Company), Incyte Corporation, Novartis, Jazz Pharmaceuticals, Autolus Therapeutics, Syndax Pharmaceuticals, Cellectis, ADC Therapeutics, Wugen, Servier, Allogene, Amgen, Astellas Pharma, Gilead Sciences, Syndax, Incyte, Orca Biosystems, and others.
Acute Lymphoblastic Leukemia Clinical Trial Analysis
Acute Lymphoblastic Leukemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ALL companies, including AbbVie, Roche (Genentech), Janssen Research & Development, Pharmacyclics (an AbbVie Company), Incyte Corporation, Novartis, Jazz Pharmaceuticals, Autolus Therapeutics, Syndax Pharmaceuticals, Cellectis, ADC Therapeutics, Wugen, Servier, Allogene, Amgen, Astellas Pharma, Gilead Sciences, Syndax, Incyte, Orca Biosystems, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us:
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP